ECSP982394A - ARILSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES - Google Patents

ARILSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES

Info

Publication number
ECSP982394A
ECSP982394A ECSP982394A ECSP982394A EC SP982394 A ECSP982394 A EC SP982394A EC SP982394 A ECSP982394 A EC SP982394A EC SP982394 A ECSP982394 A EC SP982394A
Authority
EC
Ecuador
Prior art keywords
acid derivatives
matrix metalloproteinase
arilsulfonylaminohydroxamic
present
production
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Ralph Pelton Robinson
Kim Francis Mcclure
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP982394 priority Critical patent/ECSP982394A/en
Publication of ECSP982394A publication Critical patent/ECSP982394A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a derivados de ácidos arilsulfonilaminohidroxámicos que son inhibidores de metaloproteinasa matriciales o de la producción de factor de mecrosis tumoral (TNF) y, como tales, son útiles en el tratamiento de una condición seleccionada del grupo formado por artritis, cáncer, ulceración de tejidos, estenosis, enfermedad periodontal, epidermolises ampollosa, escleritis y otras enfermedades caracterizadas por actividad metaloproteinasas matriciales, SIDA, sepsis, shock séptico y otras enfermedades que implican la producción de TNF. Además, los compuestos de la presente invención se puede usar en terapia combinada con fármacos antiinflamatorios no esteroideos.The present invention relates to arylsulfonylaminohydroxamic acid derivatives that are inhibitors of matrix metalloproteinase or tumor mecrosis factor (TNF) production and, as such, are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, stenosis, periodontal disease, epidermolyses bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock, and other diseases involving TNF production. Furthermore, the compounds of the present invention can be used in combination therapy with non-steroidal anti-inflammatory drugs.

ECSP982394 1998-02-03 1998-02-03 ARILSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES ECSP982394A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP982394 ECSP982394A (en) 1998-02-03 1998-02-03 ARILSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP982394 ECSP982394A (en) 1998-02-03 1998-02-03 ARILSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES

Publications (1)

Publication Number Publication Date
ECSP982394A true ECSP982394A (en) 1998-12-29

Family

ID=42043317

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP982394 ECSP982394A (en) 1998-02-03 1998-02-03 ARILSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES

Country Status (1)

Country Link
EC (1) ECSP982394A (en)

Similar Documents

Publication Publication Date Title
GT199800025A (en) ARILSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES.
AR009292A1 (en) DERIVATIVES OF ACID ARILSULFONILAMINO HIDROXAMICO, PROCESSES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT
PA8446101A1 (en) ARILSULFONIL HYDROXAMIC ACID DERIVATIVES
EA199900036A1 (en) METALLIC PROTEASIS INHIBITORS OF MATRIX ON THE BASIS OF PHOSPHINATES, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT
PA8444201A1 (en) CYCLE DERIVATIVES OF SULFONA
CY1108292T1 (en) DMXAA ANTI-CANCER CONTAINER
ES2153031T3 (en) ARILSULFONIL HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF MMP AND TNF.
ECSP034568A (en) PIRIMIDIN 2,4,6-TRIONA TYPE METALOPROTEINASE INHIBITORS
BG108450A (en) Aromatic dicarboxylic acid derivatives
AR003935A1 (en) COMPOUND DERIVED FROM ACID ARILSULFONILAMINO HIDROXAMICO, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND METHOD FOR ITS PREPARATION.
ES2178724T3 (en) ARILSULFONAMIDE ALPHA-SUBSTITUTED HYDROXAMIC ACIDS AS INHIBITORS OF ALFA TUMOR NECROSIS FACTOR AND MATRIX METALOPROTEINASES.
DE60312715D1 (en) USE OF THE QUINAZOLINE DERIVATOR ZD6474 COMBINED WITH GEMCITABIN AND, IF APPLICABLE, IONIZING RADIATION FOR THE TREATMENT OF CANCER
UY28081A1 (en) COMBINED ADMINISTRACINN OF AN INDOLINONE WITH A CHEMOTHERAPCUTIC AGENT FOR CELL PROLIFERACINN DISORDERS
PT1153024E (en) 2-AMINO-6-ANILINE PURINS AND THEIR USE AS MEDICINES
ECSP066421A (en) MODULATION OF THE EXPRESSION OF eIF4E
UY27169A1 (en) DERIVATIVES OF THE ISOFTALIC ACID AS INHIBITORS OF METALPROTEINASES OF THE MATRIX
BR9908084A (en) Compound, process to treat a patient afflicted by a disorder of the central and peripheral nervous system, pharmaceutical composition, and use of a compound
UY25992A1 (en) PROCEDURE FOR PREPARING TACE INHIBITORS (TUMOR NECROSIS ALPHA FACTOR CONVERSING ENZYME)
NO20071426L (en) Cancer combination therapy including AZD2171 and Imatinib
ES2194779T3 (en) 1-AMINOTRIAZOLO (4,3-A) QUINAZOLIN-5-ONAS AND / OR 5-PHOSPHODIESTERASE INHIBITING TIONAS IV.
CR6860A (en) NEW INHIBITING DIBENZOAZULENE COMPOUNDS OF THE TUMOR NECROSIS FACTOR
DE69912432D1 (en) USEFUL FOR THE TREATMENT OF CANCER THIOPHEN- AND FURAN-2,5-DICARBOXAMIDES
NO20082566L (en) Combination of AZ2171 and permetrexed
DE60311788D1 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
ECSP982394A (en) ARILSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES